AAX Biotech Enters Next Phase of Collaboration with Daiichi Sankyo Following Initial Evaluation of Opti-mAb® Technology
Swedish biotech company AAX Biotech AB today announced that its research and development collaboration with Daiichi Sankyo (TSE: 4568) has progressed into a new phase. Following an initial evaluation of AAX Biotech's proprietary Opti-mAb® technology, the companies have agreed to advance their collaboration into an anti…
Extrait seulement — cet éditeur protège son texte. Lisez le communiqué complet à la source.
Forfait Gratuit · Plus 29 $ CA ou Pro 99 $ CA/mois


